China Issues Revised GMP Draft; Compliance Expected In Stages
This article was originally published in The Tan Sheet
Executive Summary
China's latest draft guideline on good manufacturing practices for drugs offers clarity on a few key points but still leaves huge gaps that need to be filled
You may also be interested in...
China's Aging Population Spurs OTC Sales, Looks For More Options
China's over-the-counter drug market grew more than 30 percent from 2007 to 2009 to more than RMB 90 billion ($13 billion), according to health care market intelligence provider IMS Health
U.S. Pharmacopeia Moves Melamine Testing Into The 21st Century
U.S. Pharmacopeia is developing a protein testing method that cannot be "tricked" by contaminants such as melamine, unlike the existing standard for analysis
China Taking Regulatory Route To Tighten Oversight Of Health Care Sector
China aims to upgrade supervision of its entire health care sector with an array of regulatory changes for pharmaceuticals and medical devices likely this year, including good manufacturing practice guidelines, according to a leading lawyer in the area of China's life sciences-related issues and legislation